Aging testing is an essential component of medical device registration submissions, providing regulators with objective evidence that a device and its sterile barrier system remain safe, sterile, and functional throughout the claimed shelf life. This article explains the applicable standards, sample requirements, test items, accelerated and real-time aging methodologies, and frequently asked questions to help manufacturers prepare compliant shelf-life validation dossiers.
Technical Overview
Aging testing, also referred to as shelf-life or stability testing, is a core technical element of medical device registration dossiers submitted to regulatory authorities such as NMPA, FDA, and EU notified bodies operating under the EU MDR. The purpose of aging testing is to demonstrate, with documented scientific evidence, that a medical device and its packaging system maintain their intended performance, sterility, and safety characteristics from the date of manufacture until the end of the claimed expiration period.
A comprehensive aging study typically consists of two complementary programs: an accelerated aging study, which uses elevated temperature to simulate the passage of time and supports near-term product release, and a real-time aging study, which confirms the accelerated findings under actual storage conditions. Both approaches are evaluated against the following principal reference standards:
- ASTM F1980 – Standard Guide for Accelerated Aging of Sterile Barrier Systems for Medical Devices
- ISO 11607-1 and ISO 11607-2 – Packaging for terminally sterilized medical devices
- ASTM F88 – Seal strength of flexible barrier materials
- ASTM F1929 and ASTM F3039 – Dye penetration seal integrity testing for porous and nonporous packages
- ASTM F2096 – Detecting gross leaks in packaging by internal pressurization (bubble emission)
- ASTM F2338 – Nondestructive detection of leaks in packages by vacuum decay method
- ASTM D4332 – Conditioning of containers and packages for testing
- IEC 60068-2 series – Environmental testing of electromedical equipment (damp heat, dry heat, cold)
- GB/T and YY/T national and industry standard series for submissions in the Chinese market, including YY/T 0681 packaging test methods
Testing Samples
Sterile Barrier Systems and Primary Packaging
Finished packaged units are the most common aging test samples, including Tyvek pouches, header bags, thermoformed blister trays with lidding films, and flow-wrapped configurations. Samples should represent standard production conditions, be fully sealed and sterilized by the validated process, and, where relevant, be aged in their transport configuration to account for combined environmental exposure.
Polymer-Based Devices and Components
Devices manufactured from plastics, thermoplastic elastomers, silicone, adhesives, and coatings—such as catheters, syringes, infusion sets, wound dressings, and implantable polymer components—are evaluated for material degradation, embrittlement, discoloration, and loss of mechanical properties over time.
Electronic and Electromedical Devices
Monitoring equipment, diagnostic instruments, batteries, sensors, and cable assemblies undergo aging to verify long-term electrical safety, insulation resistance, and functional reliability, often in combination with IEC 60068-2 environmental conditioning profiles.
Drug–Device Combination Products
For combination products such as drug-eluting devices and prefilled delivery systems, aging studies must address both the device functionality and the chemical stability of the drug component, frequently integrating shelf-life data across both regulatory frameworks.
Sample Quantity Planning
Sample numbers must be statistically justified. Best practice requires a minimum of three independent production lots, replicate samples at each pull-back time point, and additional retained samples for repeat or investigative testing in case of unexpected results.
Testing Items
The specific test portfolio depends on the device type, materials, and intended claims, but a typical registration-oriented aging evaluation includes the following items:
- Seal strength and peel performance of sterile barrier systems (ASTM F88)
- Package integrity and leak detection (dye penetration, bubble emission, vacuum decay, visual inspection)
- Material mechanical properties: tensile strength, elongation, hardness, and flexibility
- Dimensional stability and geometric conformity
- Microbial barrier performance of porous packaging materials
- Water vapor and gas transmission rates of barrier films
- Functional and performance verification of the finished device against acceptance criteria
- Chemical indicators: discoloration, oxidation products, extractable shifts, and pH changes
- Sterility testing of aged units using compendial methods
- Biocompatibility verification when material degradation is suspected or raw materials have changed
Testing Methods
Accelerated Aging (ASTM F1980)
Accelerated aging is based on the Arrhenius reaction rate principle, which states that the rate of chemical degradation increases predictably with temperature. The standard approach uses a Q10 factor, conservatively set at 2, meaning the degradation rate doubles for every 10°C increase in temperature. The accelerated aging factor is calculated as AAF = Q10^((TAA − TRT)/10), where TAA is the accelerated aging temperature and TRT is the ambient storage temperature.
For example, to justify a two-year (730-day) shelf life for a product stored at 23°C and aged at 55°C, the aging factor is 2^((55−23)/10) = 2^3.2 ≈ 9.2, giving a required accelerated exposure of approximately 80 days. Common accelerated aging temperatures range from 40°C to 60°C, and the selected temperature must remain safely below glass transition temperatures, melting points, and other material phase transitions to avoid introducing unrealistic failure modes. Relative humidity is controlled and documented throughout exposure to prevent condensation artifacts, typically within 45% to 60% RH or at ambient humidity where justified.
Real-Time Aging
ISO 11607-1 requires that real-time aging studies be initiated concurrently with accelerated studies. Real-time samples are stored under defined ambient conditions, typically 20°C to 25°C with controlled humidity, and are tested at the claimed expiration date. Real-time data supersede accelerated predictions if discrepancies arise, and regulators expect real-time results to be reported as a post-submission commitment when the full duration has not elapsed at the time of review.
Test Sequence and Evaluation
Testing is performed at a zero-time baseline, optionally at a mid-point interval, and at the final aging endpoint. Upon removal from the aging chamber, samples are conditioned per ASTM D4332 before evaluation. Package integrity and seal strength are typically assessed first, followed by material characterization, device functional testing, and sterility verification. All results are compared against pre-established acceptance criteria derived from design validation, and any failure triggers a documented investigation and impact assessment.
Applications
Aging test reports from accredited third-party laboratories or validated in-house facilities are used throughout the product lifecycle and across multiple regulatory frameworks:
- NMPA Class II and Class III registration dossiers, supporting the shelf-life research section required by Chinese regulatory review
- FDA 510(k), De Novo, and PMA submissions, where expiration dating claims must be substantiated
- EU MDR technical documentation and CE marking under EU notified body assessment
- Shelf-life extensions, design changes, raw material or supplier changes, and sterilization process modifications
- Export registrations in markets that recognize ISO 11607 and ASTM F1980-based stability evidence
- Tender documentation and quality agreements requiring third-party verified expiration claims
FAQ
Is accelerated aging data alone sufficient for registration?
No. Accelerated aging supports the initial shelf-life claim and enables earlier market access, but regulators require a real-time aging study to be running concurrently, with results submitted or reported as they become available. Real-time findings take precedence over accelerated predictions.
How is the accelerated aging duration calculated?
Using the Q10 method per ASTM F1980: AAF = Q10^((TAA − TRT)/10), then dividing the intended shelf life in days by the aging factor. With the conservative default Q10 of 2, aging at 55°C for storage at 23°C compresses one year of real time into roughly 40 days of chamber exposure.
What aging temperature should be selected?
The temperature must be high enough to be practical yet below any material transition point such as the glass transition temperature of polymers or the softening point of adhesives and coatings. Material qualification screening is recommended before finalizing the protocol, and 50°C to 60°C is the most common range for polymer-based devices.
How many lots and samples are required?
Best practice and common regulatory expectation call for at least three independent manufacturing lots, with statistically justified sample sizes at each time point to demonstrate lot-to-lot consistency and to accommodate repeat testing.
Must the package be aged together with the device inside?
Yes. The sterile barrier system and the device should be aged as a finished, sterilized unit so that interactions between the product, the packaging, and any residual sterilant effects are captured realistically. Simulated distribution testing is often combined after aging to challenge aged packages under transport stress.
What happens if real-time results differ from accelerated data?
Any discrepancy requires a documented investigation, root cause analysis, and risk assessment. Depending on the outcome, the manufacturer may need to shorten the claimed shelf life, revise the packaging design, or notify regulatory authorities of the change to the previously supported expiration date.